LIF and metabolic dysfunction-associated steatohepatitis: Considering that the alternative pathway also amplifies complement activation due to the classical and lectin pathway activation that is known to occur in NASH, currently explored inhibitors of the alternative pathway such anti-factor B, anti-factor D, and the complement receptor 2/factor H fusion protein TT30 [6] could be attractive therapeutic agents for NASH.